Alzheimer Society Research Program provides $3.4 million boost to dementia research

TORONTO, Sept. 12, 2017 /CNW/ - The Alzheimer Society Research Program (ASRP) is pleased to announce it has awarded $3.4 million to Canadian researchers through this year's research competition to help create a brighter future for Canadians who are impacted by or at risk of Alzheimer's disease and other forms of dementia.

This year's awards and grants support 24 applicants from across the country who are working towards finding new prevention and treatment strategies, enhancing patient care, and finding a cure.

Recipients include:

Jennifer Walker, First Nations University of Canada: Jennifer is collaborating with local researchers to study the increasing rate of dementia among First Nations in Saskatchewan. Her work will help inform and improve dementia care services in Indigenous communities.

Heather Cooke, University of British Columbia: Heather seeks to better understand how incivility and bullying among long-term care workers influences dementia care. The results will help improve staffing practices and policies and enhance the quality of life for both residents and staff.

Jannic Boehm, Université de Montréal: Jannic's goal is to develop a "peptide" that will penetrate the blood-brain barrier and access neurons in the brain. If successful, this tool could be used to help maintain and promote brain function in people with Alzheimer's disease.

Matthew Parsons, Memorial University, St. John's: Matthew's research will investigate when and where toxic proteins in the brain, the hallmarks of Alzheimer's disease, begin to impair brain cells and disrupt the formation of memories. He hopes these findings will ultimately lead to new treatments.

"Research funding is critical for advancing scientific discoveries and producing breakthroughs that enable people with dementia to live well and bring us closer to a cure," says Nalini Sen, Program Director. "We're proud of our Program and to be able to provide opportunities to many of Canada's bright and talented minds."

The Alzheimer Society Research Program (ASRP) is a national leader in dementia research aimed at supporting and developing capacity in the areas of biomedical, clinical and health services research. Funding applications undergo an extensive peer-review process led by respected researchers as well as people with lived experience of dementia. The ASRP is a collaborative initiative of Alzheimer Societies across Canada, key partners and generous individual and corporate donors. Since its inception 30 years ago, the Program has invested $53 million in dementia research.

For an inside look at the ASRP and to hear directly from some of our researchers about their discoveries, watch our video at https://youtu.be/rqfQnFHOZk8. More information is also available at www.alzheimer.ca/research.

SOURCE Alzheimer Society of Canada

ProMIS Neurosciences Identifies Novel Therapeutic Epitope Target for ALS and Dementia

Company files United States patent application for novel epitope target identified on misfolded forms of the protein TDP43

TSX: PMN

TORONTO and CAMBRIDGE, MA, May 31, 2017 /CNW/ - ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of precision treatments for neurodegenerative diseases, today announced the identification of a novel therapeutic epitope target on misfolded forms of TDP43, implicated in the development and progression of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The Company filed a provisional patent application for this target with the United States Patent Office on May 30, 2017.

Commenting on today's announcement, Dr. Neil Cashman, ProMIS Chief Scientific Officer, stated: "Using our proprietary discovery engine, scientists at UBC and ProMIS identified both the sequence and conformational shape of this novel epitope target on misfolded TDP43 that plays a key role in ALS and frontotemporal dementia."

TDP43 is present in every cell, and plays a critical role in the response of cells to oxidative stress. However, in ALS, FTD and other neurodegenerative diseases, TDP43 can lose its normal function, forming intracellular aggregates of misfolded TDP43 that disrupt cellular energy generation and normal protein degradation.

"Our goal is to selectively target misfolded TDP43 without disrupting the critical role that normally-folded TDP43 plays in cell biology," stated Dr. Elliot Goldstein, ProMIS President and CEO. "We plan to create and validate monoclonal antibodies against misfolded TDP43 to select optimal therapeutic candidates for advancement into the clinic."

Pursuant to its expanded license agreement with the University of British Columbia, ProMIS holds exclusive, worldwide license to this novel therapeutic target.

About ProMIS Neurosciences, Inc.

ProMIS Neurosciences is a TSX listed biotech company (trading symbol: PMN.TO), headquartered in Toronto, Ontario and with offices in Cambridge, Massachusetts. The mission of ProMIS is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases, in particular Alzheimer's disease and ALS.

ProMIS Neurosciences' proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platform—ProMIS^™ and Collective Coordinates — to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins. Using this unique "precision medicine" approach, ProMIS Neurosciences is developing novel antibody therapeutics and specific companion diagnostics for Alzheimer's disease and ALS. The company has also developed two proprietary technologies to specifically identify very low levels of misfolded proteins in a biological sample. In addition, ProMIS Neurosciences owns a portfolio of therapeutic and diagnostic patents relating to misfolded SOD1 in ALS, and currently has a preclinical monoclonal antibody therapeutic against this target.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For further information please consult the Company's website at:
www.promisneurosciences.com

Follow us on Twitter
Like us on LinkedIn

SOURCE ProMIS Neurosciences Inc.